Cytochalasin D, LY294002 and olomoucine synergize in promoting death of melanoma cells through activation of caspase-3 and apoptosis

Melanoma Research

Volumn 20, Issue 1, 2010, Pages 52-58

  Mal̊ecki, Jȩdrzej Mieczyslaw ^a   Bentke, Anna ^a   Ostrowska, Barbara ^a   Laidler, Piotr ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Apoptosis; Caspase 3; Cytochalasin D; LY294002; Melanoma; Olomoucine; Staurosporine; Terminal dUTP nick end labeling

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CASPASE 3; CYTOCHALASIN D; OLOMOUCINE; STAUROSPORINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER STAGING; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA CELL; NICK END LABELING; PRIORITY JOURNAL; TUMOR GROWTH;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASE 3; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL SURVIVAL; CHROMONES; CYTOCHALASIN D; DRUG SYNERGISM; ENZYME ACTIVATION; HUMANS; IN SITU NICK-END LABELING; KINETIN; MELANOMA; MORPHOLINES; SKIN NEOPLASMS; STAUROSPORINE; UP-REGULATION;

EID: 75749119004     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328332f1e6     Document Type: Article

References (35)

1. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281:1309-1312.
2. Kumar S. The apoptotic cysteine protease CPP32. Int J Biochem Cell Biol 1997; 29:393-396.
3. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, et al. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly (ADP-ribose) polymerase. Cell 1995; 81:801-809.
4. Martin SJ, Green DR. Protease activation during apoptosis: death by a thousand cuts? Cell 1995; 82:349-352.
5. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91:231-241.
6. Shitashige M, Toi M, Yano T, Shibata M, Matsuo Y, Shibasaki F. Dissociation of Bax from a Bcl-2/Bax heterodimer triggered by phosphorylation of serine 70 of Bcl-2. J Biochem (Tokyo) 2001; 130:741-748.
7. Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 2001; 40:1117-1123.
8. Song Z, Yao X, Wu M. Direct interaction between survivin and Smac/ DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem 2003; 278:23130-23140.
9. Morizane Y, Honda R, Fukami K, Yasuda H. X-linked inhibitor of apoptosis functions as ubiquitin ligase toward mature caspase-9 and cytosolic Smac/ DIABLO. J Biochem 2005; 137:125-132.
10. Vaux DL, Silke J. IAPs, RINGs and ubiquitylation. Nat Rev Mol Cell Biol 2005; 6:287-297.
11. Smalley K. A pivotal role for ERK in malignant melanoma? Int J Cancer 2003; 104:527-532.
12. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003; 4:257-262.
13. Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW, et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 2004; 64:7002-7010.
14. Plettenberg A, Ballaun C, Oammer J, Mildner M, Strunk D, Weninger W, et al. Human melanocytes and melanoma cells constitutively express the Bcl-2 proto-oncogene in situ and in cell culture. Am J Pathol 1995; 146:651-659.
15. Grossman D, Kim PJ, Scechner JS, Altieri DC. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci U S A 2001; 98:635-640.
16. Li G, Satyamoorthy K, Herlyn M. N-cadherin-mediated intracellular interactions promote survival and migration of melanoma cells. Cancer Res 2001; 61:3819-3825.
17. Christofori G. Changing neighbours, changing behaviour: cell adhesion molecule-mediated signalling during tumor progression. EMBO J 2003; 22:2318-2323.
18. Ciołczyk-Wierzbicka D, Bodzioch M, Gil D, Zmudziń ska D, Dembiń ska-Kieć A, Laidler P. Expression of fucosyltransferases contributes to melanoma invasive phenotype. Med Chem 2007; 3:418-424.
19. Smalley K, Herlyn M. Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics. Ann N Y Acad Sci 2005; 1059:16-25.
20. Druker BJ. Imatinib as a paradigm of targeted therapies. Adv Cancer Res 2004; 91:1-30.
21. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353:172-187.
22. Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D, et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006; 9:341-349.
23. Li CJ, Li YC, Pinto AV, Pardee AB. Potent inhibition of tumor survival in vivo by beta-laphacone plus taxol: combining drugs imposes different artificial checkpoints. Proc Natl Acad Sci U S A 1999; 96: 13369-13374.
24. Edamatsu H, Gau CL, Nemoto T, Guo L, Tamanoi F. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene 2000; 19:3059-3068.
25. Smalley K, Haass N, Brafford P, Lioni M, Flaherty K, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006; 5:1136-1144.
26. Talanian RV, Quinlan C, Trautz S, Hackett M, Mankovich JA, Banach D, et al. Substrate specificities of caspase family proteins. J Biol Chem 1997; 272:9677-9682.
27. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995; 376:37-43.
28. Jeruc J, Vizjak A, Rozman B, Ferluga D. Immunohistochemical expression of activated caspase-3 as a marker of apoptosis in glomeruli of human lupus nephritis. Am J Kidney Dis 2006; 48:410-418.
29. Konstantinidou A, Givalos N, Gakiopoulou H, Korkolopoulou P, Kotsiakis X, Boviatsis E, et al. Caspase-3 immunohistochemical expression is a marker of apoptosis, increased grade and early recurrence in intracranial meningiomas. Apoptosis 2007; 12:695-705.
30. Zhang XD, Gillespie SK, Hersey P. Staurosporine induces apoptosis of melanoma by both caspase-dependent and -independent apoptotic pathways. Mol Cancer Ther 2004; 3:187-197.
31. Veselý J, Havlicek L, Strnad M, Blow JJ, Donella-Deana A, Pinna L et al. Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem 1994; 224:771-786.
32. Garrofé-Ochoa X, Melero-Fernández de Mera RM, Fernández-Gómez FJ, Ribas J, Jordán J, Boix J. BAX and BAK proteins are required for cyclin-dependent kinase inhibitory drugs to cause apoptosis. Mol Cancer Ther 2008; 7:3800-3806.
33. O'Connor DS, Grossman D, Plescia J, Li F, Zhang H, Villa A, et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A 2000; 97:13103-13107.
34. Tran NL, Adams DG, Vaillancourt RR, Heimark RL. Signal transduction from N-cadherin increases Bcl-2; regulation of the phosphatidylinositol 3-kinase/ Akt pathway by homophilic adhesion and cytoskeletal organisation. J Biol Chem 2002; 277:32905-32914.
35. Sunters A, Fernandez de Mattos S, Stahl M, Brosens J, Zoumpoulidou G, Saunders C, et al. FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem 2003; 278:49795-49805.